Publications by authors named "Kenneth T Luu"

Claim this Profile
R
Response to Comments on ".
Mitalee Tamhane, Kenneth T Luu, Mayssa Attar

J Pharmacol Exp Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
Kenneth T Luu, Jennifer Seal, Michelle Green, Carolyn Winskill, Mayssa Attar

J Clin Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular Pharmacokinetics of Brimonidine Drug Delivery System in Monkeys and Translational Modeling for Selection of Dose and Frequency in Clinical Trials.
Mitalee Tamhane, Kenneth T Luu, Mayssa Attar

J Pharmacol Exp Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition.
Kenneth T Luu, Jennifer R Seal, Mayssa Attar

J Pharmacol Exp Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
Kenneth T Luu, Daniel A Norris, Rudy Gunawan, Scott Henry, Richard Geary

J Clin Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and pharmacodynamics of IONIS-GCGR, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model.
Kenneth T Luu, Erin S Morgan, Sanjay Bhanot, Richard Geary, Anne Smith

J Pharmacokinet Pharmacodyn· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.
Kenneth T Luu, Joseph Boni

Cancer Chemother Pharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.
Kenneth T Luu, Eugenia Kraynov, Bing Kuang, Paolo Vicini, Wei-Zhu Zhong

AAPS J· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Luis Fayad, Fritz Offner, Mitchell R Smith, Gregor Verhoef, Peter Johnson, Kenneth T Luu

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
Kenneth T Luu, Simon Bergqvist, Enhong Chen, Dana Hu-Lowe, Eugenia Kraynov

J Pharmacol Exp Ther· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
Kenneth T Luu, Eric Y Zhang, Ganesh Prasanna, Cathie Xiang, Scott Anderson

J Pharmacol Exp Ther· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P-glycoprotein induction and tumor cell-kill dynamics in response to differential doxorubicin dosing strategies: a theoretical pharmacodynamic model.
Kenneth T Luu, James A Uchizono

Pharm Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis